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Abstract.
Background:Low participation in clinical trials is a major challenge to advancing clinical Alzheimer’s disease (AD) research
and care. Factors influencing recruitment to AD trials are not fully understood.
Objective: To identify barriers to, and facilitators of, recruitment in a UK multi-center, secondary care AD trial (Reducing
pathology in Alzheimer’s Disease through Angiotensin TaRgeting (RADAR) trial) and implications for improving recruitment
to AD trials.
Methods: Semi-structured qualitative telephone interviews with a purposive sample of 17 trial site staff explored the RADAR
trial recruitment pathway and views and experiences of recruitment. Interviews were analyzed thematically.
Results: Diagnostic and care pathways hindered identifying patients with mild-moderate AD, with a lack of up-to-date
patient records and data access problems affecting screening. Research is not routinely embedded in AD care but facilitated
recruitment when it was. Clinicians’ and patients’ favorable view of the trial purpose facilitated recruitment, although the
complexity of participant information sheets and requirement for study companion created challenges.
Conclusion: These findings have important implications for the design of future AD trials and for planning how to best
interface with clinical commitments to ensure sufficient and timely recruitment. Challenges to AD trial recruitment can occur
at care pathway, clinician, and patient and companion levels. Recruitment can be facilitated by: improving diagnostic processes
and systems for recording and sharing patient information, embedding research into routine patient care, collaborating with
a range of services to identify and approach eligible patients, training and engaging trial staff, and providing patients with
clear and concise study information.
Keywords: Dementia, humans, patient care, qualitative research, randomized controlled trial, research design
INTRODUCTION
The success of randomized controlled trials
(RCTs) relies on adequate and timely recruitment.
1These authors contributed equally to this work.
∗Correspondence to: Clare Clement, Bristol Medical School,
University of Bristol, Canynge Hall, 39 Whatley Road, Bristol,
BS8 2PS, UK. Tel.: +01179 28 7272/07870 159065; E-mail:
c.clement@bristol.ac.uk.
Common reasons for poor recruitment to RCTs
include potential participants’ understanding of trial
processes such as randomization [1], patient and
health professional preference for particular treat-
ments [2–4], and barriers to communication across
trial sites. A review of 24 multi-site phase II and III
Alzheimer’s disease (AD) clinical trials found that
only a third were able to recruit sufficient partici-
pants within a year [5]. AD trials may face additional
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recruitment challenges due to complex medication
regimes excluding patients with advanced cognitive
impairment, and the need to recruit a study partner
or companion alongside a patient for when the dis-
ease progresses. While patient burden must always
be balanced with safety monitoring, the age of the
AD population and the presence of co-morbidities
can make this particularly challenging [5, 6].
Although a recent Cochrane review identified 68
studies evaluating strategies to improve RCT recruit-
ment, none of these strategies had been tested in AD
populations [7], and there is a paucity of empirical
evidence supporting trial recruitment in this clin-
ical area [5, 6]. Qualitative research can improve
trial recruitment in some cases, [8, 9] but has not
yet been applied to an AD trial [10–13]. This study
aimed to identify potential challenges to, and facili-
tators of, recruitment to the Reducing pathology in
Alzheimer’s Disease through Angiotensin TaRget-
ing (RADAR) RCT, and to draw out implications for
improving recruitment to AD trials more widely [14].
METHODS
Semi-structured telephone interviews were con-
ducted with clinicians and trial staff recruiting to the
RADAR trial, a phase II multi-center RCT comparing
effects of 100 mg losartan with placebo on changes
in brain whole atrophy in patients with AD (Trial
Registration Number ISRCTN93682878) [14]. Inclu-
sion criteria were diagnosis with mild-moderate AD
and at least 55 years old. The trial took place in a
total of 23 sites which were specialist UK National
Health Service (NHS) hospital trusts that routinely
diagnose AD. Participants enrolled in the trial under-
went an initial open label phase. If successful, they
were randomized to either losartan or placebo for 12
months. Patients and trial personnel were blinded to
the treatment arms for trial duration. The primary
outcome, rate of whole brain atrophy as a surro-
gate measure of disease progression, was assessed
through a magnetic resonance imaging (MRI) scan
at 12 months. Recruitment for the trial took place
between July 2014 and May 2018. The recruitment
target was 228 and final recruitment was 211 patients
(92.5%). Initially 10 sites were to be included in the
trial, but low recruitment led to more sites being added
and the timeline for the trial being extended.
Sampling
Interview participants were purposively sampled
to include research nurses and doctors screening and
consenting patients, from trial sites with high and
low recruitment rates compared to targets. The tar-
get recruitment rate per site was 0.4 patients per
month;≥0.4 was categorized as a high recruitment
rate and <0.39 as low.
Data collection
Semi-structured telephone interviews were con-
ducted by CC, LES, and JH, experienced qualitative
researchers, independent of the trial team. Partici-
pants were unknown to the interviewers beforehand.
Participants were informed of the study aims and
purpose of the interviews. A semi-structured topic
guide (Box 1) was used to assist questioning during
the interview while allowing participants to intro-
duce unanticipated issues. Data collection continued
until theoretical saturation, i.e., later stages of
analysis resulted in no new themes being identified
[15]. Interviews were conducted between July and
October 2016 when the trial had been recruiting for
23 months.
Box 1. Summary of topic guide
Interview topics for discussion:
The site recruitment pathway
Views on and examples of explaining the trial details to patients;
• Randomization
• Uncertainty and informed consent
Patient views of the trial and potential preferences regarding trial arm allocation
Positive and negative aspects of recruitment
Recommendations for improving recruitment to future AD trials.
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Table 1
Thematic summary of barriers (–) and facilitators (+) to recruitment
Theme Barriers (–) Facilitators (+)
1. System AD diagnostic pathway linking up systems with other sites
poor record keeping and quality of information
(local)
establish links with other services and recruitment
avenues
research not embedded in culture of AD care make research part of standard treatment options
lack of/inaccurate information on national database multiple staff members using national database
resources needed to use the national database
self-selected nature of patients on national database
2. Healthcare
Professionals
gate-keeping personal knowledge/direct contact




requirement for research partner/companion presentation of clear, simple and concise information
research partner/companion acting as a gate-keeper follow-up with patient
overly complex/unnecessarily detailed
language/materials
prior patient involvement in research
insufficient information on key topics patient belief in the trial and its benefits
concerns for clinical condition and prolonged
participation
preference for active arm
Data analysis
All interviews were audio recorded, profession-
ally transcribed verbatim, imported into NVivo 10
[16] and analyzed using thematic analysis [17] and
constant comparison techniques [18, 19]. CC, LES,
and JH independently coded three transcripts to
establish initial coding frames. Coding was both
inductive, identifying patterns and themes in the data
which addressed important issues for participants,
and deductive, focused on trial recruitment [20]. Ana-
lysts then met to discuss emerging findings and agree
a final coding frame. CC and LES applied the final
coding frame to all transcripts. Themes and sub-
themes were compared within and across interviews
and sites to identify patterns and confirming and dis-
confirming instances. Our research was in the subtle
realist paradigm, in which reality is conceptualized
as existing objectively, but known only from each
individual’s own perspective.
Ethics, consent, and permissions
All procedures contributing to this work comply
with the ethical standards of the relevant national
and institutional committees on human experimen-
tation and with the Helsinki Declaration of 1975,
as revised in 2008. All procedures involving human
subjects/patients were approved by NHS Research
Ethics Committee (12/WA/0338). All participants
gave informed consent and agreed to anonymized
quotes being used in publications. In presenting
findings, data have been anonymized to protect con-
fidentiality. Data extracts are presented by trial site
number, role of interviewee and whether the site
was high or low recruiting (e.g., Site 2, Doctor, high
recruiting).
RESULTS
Interviews were conducted with 17 healthcare pro-
fessional participants. Seven were doctors and ten
nurses who were either research nurses or research
coordinators involved in patient recruitment. Partici-
pants were sampled from 10 of the 23 trial sites across
the UK, 5 sites were high recruiting (8 participants
interviewed), and 5 sites were low recruiting (9 par-
ticipants interviewed). Interviews lasted between 11
and 90 minutes (mean 36 minutes).
Challenges to and facilitators of recruitment
related to three themes: 1) Systemic factors (AD diag-
nostic pathway, patient records, embedding research
in patient care, and the national research database),
2) Healthcare professionals, and 3) Patients and their
companions (see Table 1 for summary).
Theme 1: Systemic factors
System-level challenges and facilitators occurred
in four main sub-themes: the diagnostic pathway,
patient records, embedding research in patient care,
and the national research database.
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AD diagnostic pathway
Interviewees reported that patients with AD are
currently most often diagnosed later in the disease,
and most mild-moderate AD patients go undetected.
This made it difficult to identify patients with mild-
moderate AD who might be eligible for the trial.
“It’s just working in a system where it’s hard
to find people where they’re not diagnosed until
late . . . That’s probably the main [difficulty]: just
finding the right people, so someone that’s had a
diagnosis of [AD] and they’re in that mild to mod-
erate category so, yes that can be challenging.”
(Site 2, Doctor, high recruitment)
Interviewees also reported that AD was being
increasingly diagnosed in primary care, and that
patients with mild-moderate AD therefore did not
necessarily access the services, such as memory clin-
ics, where the trial was recruiting.
“[The consultant] doesn’t necessarily get an
awful lot of patients through the clinic that would
be eligible for us . . . often patients aren’t referred
to a memory clinic [by their GP]. People cope
with the dementia without asking for help for
a long time . . . They don’t get an awful lot of
follow-up once they’re diagnosed as well.” (Site
4, Nurse, high recruiting)
The specialist nature of some AD clinics meant the
patient pool was even more limited.
“That’s a relatively small pool of people because
our clinics are tertiary referral clinics, so we tend
to get some people with the unusual dementias
rather than very standard Alzheimer’s disease.”
(Site 2, Doctor, high recruiting)
To address this, several higher recruiting sites had
established links with primary care and engaged with
a wide range of services and recruitment avenues out-
side the clinic. These included using the national Join
Dementia Research (JDR) database, [21] community
memory services, specialist and research nurses, as
well as advertisements and media publicity.
“We also have good links with the psychiatric
nurses in [area] and they followed us on you know,
they might see patients on their caseload, they
typically will come back to us and say, ‘You know,
so-and-so has been tested and is eligible’ and then
we might pursue a potential participant that way
as well.” (Site 3, Nurse, high recruiting)
Linking with and using additional recruitment
avenues required understanding, engagement, and
planning with local services early on in trial develop-
ment.
“It’s just linking with the right clinics and clini-
cians or GPs, wherever they’re being diagnosed,
so then that has its challenges because every-
where’s doing it differently in the UK . . . there’s
lots of different streams and systems. So, it’s just
getting your head around who does what, who’s
gonna have communication with these patients
and then making sure you’ve got all the right
agreements in place. That can be quite a lot to get
your head around.” (Site 2, Doctor, high recruit-
ing)
Patient records
Interviewees relied on patient medical records and
local research databases for pre-screening, so poor
quality record-keeping or IT access problems hin-
dered the identification of eligible patients.
“Our electronic records may not document what
medication they’re on at the moment, because our
system is a mental health system and it doesn’t
link up with the GP system . . . so we probably
haven’t got their current up-to-date medication
so, yeah, that can be quite difficult”. (Site 5,
Nurse, low recruiting)
Local research databases of patients who had
agreed to be approached about relevant research stud-
ies were rarely regularly updated, which resulted in
staff contacting patients who were ineligible.
“We also had a database that we went through,
but the database is quite old, so a lot of patients
were too old or too unwell to take part when they
were given the opportunity.” (Site 4, Nurse, high
recruiting)
In contrast, one interviewee at a high recruiting
site discussed how linking up systems with other sites
aided patient identification and screening:
“Our system is quite good in [area] ‘cause there’s
a lot of notes that have been scanned in from
other hospitals so you can actually view them.
It depends on how local the hospitals are, but
they’ve also got a scan store thing, so [if] they’ve
had like an MRI or CT [computerised tomog-
raphy] scan in another health board, you can
look that up on the [system] as long as you have
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their identification number.” (Site 4, Nurse, high
recruiting)
Embedding research in patient care
Research not being embedded in the culture of AD
care across services contributed to difficulties identi-
fying and recruiting participants.
‘It’s more bedding the research into the culture . . .
because when people are given a diagnosis of
dementia there’s a huge emphasis on living well,
accepting it and not having unrealistic expecta-
tions, coping with the emotions of it . . . I think
research doesn’t get mentioned.’ (Site 2, Doctor,
high recruiting)
To address this, staff at high recruiting sites
asked all patients for consent to be contacted about
future research on admission to the service. This
facilitated easier identification and recruitment and
helped ensure all patients had access to research
options.
“So as part of the clinic we automatically obtain
consent or not . . . to be contacted about stud-
ies . . . what’s certainly pretty good is that people
are happy to be consented to be contacted. So
that’s been for . . . a number of years . . . part
of the routine procedure in clinic, to have this
consent in place”. (Site 6, Doctor, high recruiting)
National research database
Most staff at high recruiting sites discussed using
the JDR national database for trial patient identifi-
cation. People with dementia and their carers can
sign up online to join the JDR and register their
interest in taking part in dementia research. Staff
at lower recruiting sites discussed using JDR but
not as actively as the higher recruiting sites; they
adopted a more “passive approach” (Site 9, Nurse,
low recruiting) and extra resources were needed to
use it effectively.
All those who used JDR discussed the same
challenges using the database: it lacked clarity on
patients’ exact diagnosis, progression status and
capacity, and information on patients’ participation
in other research studies was often not current. Inter-
viewees felt JDR needed to be updated regularly to
remain relevant and useful. Most patients identified
through JDR were unsuitable.
“The Join Dementia Research website keeps me
very busy [laugh] . . . I think we’ve recruited one
person from there, but there’s always lots of peo-
ple to look at. Whether they are suitable is another
thing.” (Site 2, Nurse, high recruiting)
Owing to the incompleteness of the JDR, trial staff
had to spend considerable time contacting poten-
tial participants to discuss missing information and
gain their consent to seek out additional information
before they could reliably identify them as trial-
eligible.
Interviewees had only limited time within their
busy workload to dedicate to the trial. They suggested
that having multiple members of the trial team screen-
ing and approaching patients from JDR would benefit
recruitment.
“Just having more than one person pre-screening
so you’ve always for people following up peo-
ple . . . I think that does take up a lot of time . . . it
does help if you’ve got two or three of you.” (Site
2, Nurse, high recruiting)
Theme 2: Healthcare professionals
The clinicians interviewed expressed positive
views of the trial purpose, design, and leadership
which led them to want to be involved.
“There are no treatments for dementia or
Alzheimer’s disease. [Losartan] is a very cheap,
easy medication to give that we already know is
very safe and there’s a good scientific rationale
so, you know, even if there was any benefit at
all from it [Lorsatan] would be a big step up for
people.” (Site 2, Doctor, high recruiting)
Clinicians preferred to approach patients from their
own clinics for trial recruitment, “because you know
them” (Site 3, Doctor, high recruiting), and assessing
eligibility for the trial through known medical history
was straight-forward.
“Well, the ones who we have from a PI [Prin-
cipal Investigator]’s clinic, you will already be
aware of their medical history and things, which
is probably why that’s the most successful recruit-
ment method up here, because we’re aware of the
medical history against the inclusion/exclusion
criteria.” (Site 3, Nurse, high recruiting)
However, interviewees described some clinicians
being paternalistic with their own patients and act-
ing as gate-keepers, restricting the number of patients
they approached about a trial.
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“A lot of clinicians are very reluctant to quote
‘allow’ unquote their patients to go into research.”
(Site 3, Doctor, high recruiting)
Few interviewees had undertaken any “formal
training” (Site 6, Doctor, high recruiting) in recruit-
ment to trials, and most relied on previous experience
and learning on the job. Some interviewees identified
issues with explaining the trial to patients, particu-
larly randomization and the necessity for a placebo
arm, and found it “hard to manage people’s expecta-
tions.” (Site 2, Nurse, high recruiting). They felt they
would benefit from training on how to deal with these
issues.
“I think sometimes at the end it’s sort of blus-
tering around a bit and not feeling confident . . .
that’s not robust and I think we need to remember
that when we express it to our patients . . . I think
that would be a useful thing to have some sort
of training and . . . based on evidence in how we
express trials to patients, how we convey the need
for placebo and the need for the rigour.” (Site 2,
Doctor, high recruiting)
Interviewees reported that having a platform to
communicate with other sites (e.g., newsletters and
joint conference calls) could help them discuss suc-
cesses and challenges and allow them to learn from
each other. This would, they believed, help increase
recruitment at sites.
“We could see . . . which site is really recruiting
well and get in touch with them and say, like,
‘What are you doing to recruit really well? Is there
something that we can do?”’ (Site 4, Nurse, low
recruiting)
Theme 3: Patients and their companions
One of the main challenges to patients taking part
in the trial was the eligibility requirement of having
a research companion (an informant) support them
through the trial; many of the patients approached
did not have an appropriate person or did not want
to burden a family member or friend. The number of
research visits, held during working hours, made this
more challenging.
“Another criteria that does exclude a few people
actually is they have to have someone who we call
an informant who will come with them to certain
visits, so I think it’s the screening, baseline, six
months and twelve month visits they would have
to come with someone, and actually quite a lot
of people live on their own and then they feel
like, oh, ‘I can’t ask my son or daughter because
they’ll be too busy,’ or ‘I don’t really want my
friends to come with me’. Because we do ask the
informant quite a lot of questions about the partic-
ipant, about their memory and how they are and
how they seem, so that can exclude quite a lot of
people as well.” (Site 2, Doctor, high recruiting)
Potential research companions were sometimes
gatekeepers to patient recruitment, and managing
both patients’ and companions’ expectations of the
trial could be challenging for staff.
“Well, it’s usually the informant to be honest . . .
Occasionally the individual will say, ‘No, I don’t
think I’m up to that.’ But usually it’s [the] com-
panion, ‘I don’t think they’ll be able to do it,’ you
know.” (Site 3, Doctor, high recruiting)
Patients themselves could potentially be deterred
by the trial participant information sheets, which were
perceived as lengthy and complicated.
“Once we do invite them to the screening visit,
we then have to send another patient informa-
tion sheet, patient information sheet 2 and then
another information sheet for the informant as
well and that’s quite a lot of paperwork . . . to
send. So I think some people when they get that
are a bit like, ‘Wow! There’s a lot of information
to take in.”’ (Site 2, Nurse, high recruiting)
Patients and their informants commonly asked for
clarification of the written information. Most queries
related to the number and location of research vis-
its, drug side effects, monitoring, what would happen
once the study ended, and whether they would be
informed about study results.
“[Patients] want to have more [reassurance]
around the fact that . . . they don’t have to come
to sites for all their visits . . . and they typically
want to ask maybe a few more questions about
the drug.” (Site 3, Nurse, high recruiting)
“Usually people ask about side-effects.” (Site 6,
Doctor, high recruiting)
Interviewees highlighted the need to stagger and
reiterate information and the benefit of multiple
opportunities to discuss the trial, either in clinic or
by phone.
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“I try and make it as simple as possible . . . we give
them opportunities to ask more questions. I try not
to use words that they may not understand. I try
and simplify the discussion as much as possible.”
(Site 9, Doctor, low recruiting)
“We normally telephone them just because we
find that works best, [rather] than just sending
them out information and hoping that they will
read and understand it.” (Site 3, Nurse, high
recruiting)
The length of the study and the treatment meant
patients feared they would not be able to last the dura-
tion; they felt they would be too unwell or too fragile
or that they might not be able to take the medication
as required.
“The main reasons [for not taking part] really are
[that] . . . they feel their own health might not last
for a year, or things are a bit fragile at home for
instance, you know . . . or they might not be able
to guarantee that they would take the medication
for a year.” (Site 3, Doctor, high recruiting)
Interviewees described most patients being happy
with the possibility they may be allocated to
the placebo arm. However, some interviewees had
experienced people declining or withdrawing partic-
ipation for this reason.
“If she was on placebo, they [patient and com-
panion] would probably not continue the trial . . .
and then they did feel she was on placebo, so they
didn’t continue the trial.” (Site 2, Doctor, high
recruiting)
Patients’ and companions’ positive views of the
trial and what it was trying to achieve facilitated par-
ticipation. They saw the trial as potentially benefitting
themselves and others in the future.
“I mean some of them would hope that they had
some benefit from the trial, even if it’s just to be
looked after more carefully and . . . I mean they
don’t know if they are going to have benefit or not
but at least the trial is going to be useful to future
generations.” (Site 4, Nurse, high recruiting)
Patients and their companions also liked that the
trial was run by a University, with no financial interest
in the outcome.
“Some quite appreciate the fact, you know, that
they’re taking part in a university-led trial . . .
there are some participants who just don’t support
the whole commercial kind of thing, you know the
big money-making organisation and they do quite
like the fact that it’s a university associated trial.”
(Site 3, Nurse, high recruiting)
DISCUSSION
Main ﬁndings
This study provides an in-depth and novel exami-
nation of the views and experiences of those involved
in recruiting to an AD trial, sampled from a range
of high and low recruiting sites. Barriers to trial
recruitment included systemic factors as well as fac-
tors related to healthcare professionals, patients, and
their companions, and are likely to have relevance
to other AD trials. Current diagnostic pathways and
data systems and poor-quality record-keeping made
identifying and screening patients difficult. Rou-
tinely embedding research into patient care helped
facilitate recruitment. Clinicians preferred to recruit
from their own clinics, but this could result in
gatekeeping and restricted access for potentially
eligible patients. Interviewees lacked formal recruit-
ment training and believed that communication with
other recruiters could help facilitate learning and
improve recruitment. The study’s requirement of a
research companion was a major challenge, com-
pounded by the timing and frequency of trial visits.
Participants were put off trial participation by lengthy
and complicated trial information and often had
queries regarding key aspects of the trial. Given the
progressive nature of AD, patients were wary of
taking part in a trial with a year of treatment and
follow-up. Potential participants having a positive
view of the trial, who was running it, and what it
was trying to achieve helped facilitate recruitment.
Findings within the context of wider literature
Our results are consistent with previous studies
highlighting that patient burden and a requirement
for a study partner impact willingness to take part in
an AD trial [6]. Grill and Karlawish [5] highlighted
that traditional clinic visits taking place during the
working day could restrict caregivers acting as study
partners and therefore prevent patients participating.
Our findings are also consistent with those of Wat-
son and colleagues [6], who report a lack of AD
diagnostic tools in primary care limiting identifica-
tion and trial recruitment. We found that inadequate
explanation of trial processes such as randomization,
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resulting in lack of patient understanding, impacted
recruitment. This is consistent with recruitment barri-
ers well-documented in non-AD trials [1]. The extent
to which research is embedded in AD care has also
been highlighted as a challenge to dementia research
participation, with a recommendation that physicians
routinely discuss referral to dementia research with
their patients [22]. We found additional challenges
in recruitment related to record-keeping and access
to accurate patient information; lack of recruitment
training and linkage between trial staff; and long,
complex information sheets. Gatekeeping by health-
care professionals is a problem in other types of trials
[23] where there is lack of equipoise; however, our
findings indicate that the perceived vulnerability of
patients with AD may further compound the problem,
restricting opportunities for patients to participate.
Our findings also highlight the influence of who is
running the trial on patients’ willingness to take part.
Strengths and weaknesses
The study included a range of recruiting staff at
trial sites with differing recruitment rates. This study
also benefits from a focus on mild-moderate AD,
which previous studies have not addressed in depth.
However, we did not capture patients’ or their com-
panions’ voices, and this should be considered when
interpreting our findings. It may be that in explor-
ing their perspective, additional insights and therefore
enhanced recommendations could be made.
Implications for trials in AD
Trial designs need to take into account the diffi-
culty of identifying eligible participants by having
pragmatic trial entry criteria and realistic recruitment
projections. To facilitate recruitment, participant
information should only contain essential informa-
tion and be designed with input from Patient and
Public Involvement (PPI) contributors, while adher-
ing to research governance requirements. The timing
of participant and companion visits should be flexi-
ble to improve convenience and kept to a minimum
to reduce burden. Site staff should be provided with
recruitment training, and research nurses and clini-
cians linked via newsletters and teleconference calls
to enhance communication, training and site enthu-
siasm.
On the basis of our findings, we recommend
that 1) steps are taken to improve diagnostic ser-
vices and the way information about AD patients is
recorded and shared, 2) opportunities to participate in
research are routinely embedded into standard patient
treatment/care pathways, 3) there is less reliance
on individual clinicians, services and databases for
recruitment, and increased linkage and use of a wide
range of services and approaches to identify and
recruit patients, 4) trial teams capitalize on enthu-
siasm for AD trials; for example, through sharing
patient stories or testimonials.
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